ISLA-101
ISLA-101 is a clinical-stage antiviral therapy being developed for the prevention and treatment of dengue fever and other mosquito-borne diseases.
islandpharmaceuticals.comCrawled Nov 17, 2026
ISLA-101 is a clinical-stage antiviral therapy being developed for the prevention and treatment of dengue fever and other mosquito-borne diseases.
Leveraging existing clinical data and proven compounds to accelerate the development of high-impact antiviral therapies.
A clinical-stage antiviral with demonstrated activity across more than 20 RNA viruses, supported by significant prior investment and a strategic regulatory pathway.
Explore Island Pharmaceuticals' antiviral development pipeline, including Galidesivir and ISLA-101, and programs targeting high-priority infectious diseases.
The page provides updates on Island Pharmaceuticals’ ASX announcements, financial results, and company developments.
The page lists media coverage, news articles, and interviews about Island Pharmaceuticals, its antiviral pipeline, and corporate developments.
The page features visual content related to Island Pharmaceuticals’ science, strategy, and development initiatives.
Access Island Pharmaceuticals' corporate directory, including registered office details, share registry, ASX information, auditors, legal advisers and key contacts.
Dr. Amy Patick consults on antiviral drug discovery, viral resistance, and emerging virus epidemics, with prior roles at Adamas Pharmaceuticals and Genelabs Technologies.
Jason Carroll has held senior leadership roles in R&D and corporate strategy at Johnson & Johnson, Janssen Pharmaceutica, and iNova Pharmaceuticals.
The company’s board and management team include executives with experience in pharmaceutical development, clinical operations, and corporate strategy.
Nick McCoy has over 20 years of experience in clinical research across pharmaceutical, biotechnology, and medical device industries.
Professor Stephen Thomas led the Pfizer/BioNTech Phase III COVID-19 vaccine trial and has published research on dengue fever, Zika, and other infectious diseases.
Island Pharmaceuticals is a clinical‑stage biotechnology company focused on accelerating the development of antiviral treatments for diseases with significant unmet medical needs, including mosquito‑borne and high‑consequence viral threats.
Island Pharmaceuticals’ Corporate Governance Plan outlines the policies and procedures that guide the company’s operations and decision-making processes.
Island Pharmaceuticals is developing clinical-stage antiviral therapies targeting high-impact infectious diseases through a differentiated drug repurposing strategy.
Island Pharmaceuticals’ privacy policy outlines how it collects, uses, and manages personal information in compliance with privacy principles.